Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional

Gastrointestinal (Colorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.

François Quenet

LBA3503

Additional chemotherapy with 5-FU plus leucovorin between preoperative chemoradiotherapy and surgery improved treatment outcomes in patients with locally advanced rectal cancer.

Edward Hyunseung Oh

e15682

Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.

Winson Y. Cheung

3601

Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.

Anna Dorothea Wagner

3603

Can fit elderly patients evaluated by comprehensive geriatric assessment with intermediate or locally advanced rectal cancer receive preoperative chemoradiotherapy? An interim analysis of a multicenter phase II trial.

Wen-Yang Liu

e15688

Capecitabine maintenance in high risk loco-regional colorectal cancer.

Albina Kibirova

e15695

CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).

Harry H. Yoon

3598

Cumulative dose of oxaliplatin in adjuvant therapy for stage III colon cancer patients: Impact on survival.

Jolanta Zok

e15671

Development of a nomogram for predicting survival in microsatellite stable patients with resected colorectal cancer.

Yaqi Li

e15679

Distribution of lymph node metastases and impact on survival benefit of oxaliplatin-containing chemotherapy in stage III colon cancer.

Byung Woog Kang

e15683

Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.

Anthony Frank Shields

3599

Effect of increasing radiation dose for rectal cancer patients with nonoperative management after neoadjuvant chemoradiotherapy.

Jinghua Tang

e15676

Evaluation of treatment strategies in stage II and III rectal cancer: An NCDB Analysis.

Shreya Sinha

e15677

Final analysis of a randomized placebo-controlled double-blind phase II trial of perioperative cimetidine (CIM) in early colorectal cancer (CRC).

Michael B. Jameson

e15678

Fish oil supplementation and inflammatory response during neoadjuvant chemoradiation for rectal cancer: Results from a prospective, randomized, controlled trial.

Juliana De Aguiar Pastore Silva

3605

Germline mutation of the APC gene with classic form of familial adenomatous polyposis.

Irina Yu. Efimova

e15694

Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.

AMR Mohamed

3604

Impact of oral glutamine intake on the cycle numbers of adjuvant FOLFOX treatment administered in low and high risk colon cancer patients.

Yousuf Al-Farhat

e15691

Mesorectal excision with or without lateral lymph node dissection for clinical stage II, III lower rectal cancer: Long-term follow-up data of Japan Clinical Oncology Group study JCOG0212.

Mitsuyoshi Ota

3607

Modified FOLFOX6 with or without radiation in neoadjuvant treatment of locally advanced rectal cancer: Final results of the Chinese FOWARC multicenter randomized trial.

Yanhong Deng

3502

NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy.

James J. Lee

e15681

NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.

Thomas J. George

TPS3624

Overcoming the barriers to the use of short course radiation therapy in locally advanced rectal cancer: A phase 1 study of short course radiotherapy concurrent with 5-fluorouracil.

Emma Charlotte Fields

e15673

Pathologic complete response (pCR) after neoadjuvant treatment in rectal cancer: Multi-institutional results in Spain.

Carles Pericay

e15690

Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?

Prunella Louise Blinman

3602

Patterns of care and outcomes with the addition of radiotherapy to surgery for stage I rectal adenocarcinoma.

Nan Zhao

e15687

Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer.

Joleen Marie Hubbard

TPS3623

Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.

Theodore S. Hong

e15674

Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach.

Lifeng Yang

3608

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.

Hans-Joachim Schmoll

3500

PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).

Jaafar Bennouna

TPS3622

Prognostic impact of CDX2 in stage II colon cancer: Results from two nationwide cohorts.

Torben Hansen

3610

Prognostic value of lymph node yield in locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Yaqi Wang

e15680

Reasons for urban-rural differences in colon cancer outcomes: A population-based analysis.

Nicholas Adam Bosma

3609

Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma.

Ofer Margalit

e15686

RIA: Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial.

Carlos Fernandez-Martos

3518

Safety and tolerability of adjuvant FOLFOX vs. CAPOX in colon cancer: A real-world experience.

William J Mullally

e15689

Total neoadjuvant treatment versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective phase II clinical trials.

Jianwei Zhang

3600

Watch and wait management of rectal cancer after neo adjuvant treatment, short-term outcome and morbidity of salvage surgery: A single center experience.

Mohammed Alharthi

e15692

Who should undergo lateral pelvic node dissection after neoadjuvant chemoradiation for rectal cancer?

Songphol Malakorn

3606